What Happened?

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This added layer of uncertainty reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains. 

Also President Trump indicated he was willing to accept pain in the short term, and was aware his policies could cause a recession, but he remained more mindful of a more severe case of economic depression (higher unemployment and prolonged downturn). 

For investors, this suggested that the administration could prioritize long-term structural shifts over near-term economic stability, further increasing policy-driven risk in the markets.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, following stocks were impacted:

• Outpatient & Specialty Care company Select Medical (NYSE: SEM) fell 5%. Is now the time to buy Select Medical? Access our full analysis report here, it’s free.
• Healthcare Technology for Providers company Phreesia (NYSE: PHR) fell 5.9%. Is now the time to buy Phreesia? Access our full analysis report here, it’s free.
• Branded Pharmaceuticals company Eli Lilly (NYSE: LLY) fell 6.8%. Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
• Branded Pharmaceuticals company Pfizer (NYSE: PFE) fell 5.3%. Is now the time to buy Pfizer? Access our full analysis report here, it’s free.
• Safety & Security Services company Brink's (NYSE: BCO) fell 5.2%. Is now the time to buy Brink's? Access our full analysis report here, it’s free.

Zooming In On Eli Lilly (LLY)

Eli Lilly’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

Eli Lilly is down 9.7% since the beginning of the year, and at $702.50 per share, it is trading 26.8% below its 52-week high of $960.02 from August 2024. Investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $4,867.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.